Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

New York, USA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight The WEGOVY market has experienced significant ...

Deciding which jab to nab? When it comes to shedding pounds and cinching inches, a new study puts one weight loss drug ahead of another. Published in the New England Journal of Medicine, the study ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this ...

For weight loss, people on Wegovy lost about 13.7% of their body weight - that’s around 33 pounds. While those on Zepbound lost 20.2%, or about 50 pounds. For waist size, Wegovy users lost an ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers ...

The pharmaceutical company that makes the weight-loss drug Wegovy and the diabetes medication ... action if they continued to make or dispense compounded semaglutide products beyond April 22.

compared to nearly 14% for Wegovy users. What's more, waist size also shrank by an average of 7 inches with Zepbound and about 5 inches with Wegovy. The medications work by mimicking hormones that ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.

"It's about the size of a small city," says David Ricks ... Sponsor Message And on Wednesday the maker of Wegovy, a similar weight-loss drug, announced that it, too, would offer direct-to-consumer ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.